The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Some good signs still John!
Out o 4th past 8 trading days, 6 of them were blue. Actually on a 3 day blue streak at the moment (which I think sucks actually, because 4 in a row is a big ask).
Buying pressure is there. Loads of sticky long buyers. We have two problems - the heavy shorts which have suppressed the price (but need bought back at some point) and super bad volume. Check this out:
https://ibb.co/414ydjw
That's why there a few of us complaining about news flow. It's a volume issue. Market needs to keep NCYT in its sights. AIM doesn't have main market exposure and very little media, so we need regular RNS and stock promotion. Another RNS this week and next and that would get volume up in August I think.
@ Louis
Hard to say, but it can't be any faster than 20 days due to a requirement between notification and a legally required meeting.
Could be as fast as 2 to 3 months I guess. Looking at real world examples would be good. Interested myself, will add it to my list of crap to do some day. Dominos Pizza, Boohoo etc all good examples.
Also saw a post about Bruker maybe being the antibody partner. I think Bruker is already CE approved with their antibody test. Possible though. Could be anyone really but I'd love a powerhouse like ASZ for sheer scale and market penetration.
Brentw,
I thought that was the solution too. But even after filtering him, he still spams up the board and there will always be a stream of people replying. It needs to be dealt with before the next RNS, where he will be here spamming again.
I think the only solution really is that everyone agrees to report him at this stage. Only way it'll get resolved. If everyone filters him he gets a free pass to spam misinformation.
@ Long9
It's about disruption. We had so much to discuss yesterday and nothing really got discussed in any real depth or detail. Just superficial arguments. The whole day was consumed by that. Anyone looking at the RNS then popping in here just sees a mess, instead of information to make a sound decision on.
Doesn't have a big effect on the share price, but it can be off-putting and misleading ideas get spread that way too. It's the age of mis-information and sentiment. Ignoring that would be naive of us.
Tenders starting to be handed out already this morning. Nothing in this area yet though, mostly care home awards.
http://bidstats.uk/tenders/?sector=health
@ak
There was a short ban after the crash, so we know these shorts came after May 18th when the ban expired.
Since then Novacyt's short history has been:
Airain 0.53% 8th June
Airain 0.31% 9th June
Voleon 0.51% 23rd July
If the 0.1% rule is correct then wee have a good idea when the shorts were opened, but I think I saw before a different rule saying it was 0.2% or so. Need to check that later and see what the rules were and are.
@ ak shorts are here:
https://bdif.amf-france.org/en_US/Resultat-de-recherche-BDIF?formId=BDIF&DOC_TYPE=BDIF&LANGUAGE=en&subFormId=dpcn&BDIF_TYPE_INFORMATION=BDIF_TYPE_INFORMATION_DPCN&TEXT=&BDIF_RAISON_SOCIALE=NOVACYT&bdifJetonSociete=RS00005391&REFERENCE=&DATE_PUBLICATION=&DATE_OBSOLESCENCE=&valid_form=Start+search&isSearch=true
Can bookmark it and check daily
Current Euro rules on short thresholds (0.1% or above)
https://www.esma.europa.eu/press-news/esma-news/esma-requires-net-short-position-holders-report-positions-01-and-above
Even if they can find a large seller to buy through some broker, at the very best they'd be talking £15 million to sell those 580k shares in total.
Share price would explode. I reckon Voleon reduce their position first. It's too large and too risky. When Airain increased their short and triggered the notification, it was about a week I think until they reduced it again. Their initial short could have been opened at any price if it was under threshold, so we don't know. Could have been £4 or whatever and might not close until later. At least when Airain opened or increased that short it was smart, during a huge bear raid, well timed with another selloff.
Same as Voleon, part of the short we can't comment on, but we definitely know at least some of it was opened around the 270p mark. Pretty stupid, unless it's there as a hedge and they've got a chunky long position also.
Thinking the same, because even if they change to quarterly sales updates, they've said recently they'll provide an update on the US. Tenders would need to be RNS'd too.
Gap up over 300 tomorrow morning would be perfect.
Actually thinking about it. If they can go wild and shock us with a huge R&D update, who's to say they won't do the same with a massive sales, contract and partnerships update next. That would be wild.
One more bit of news this week would do it for us. Keep NCYT's news rolling.
Fingers crossed. Anything at all.
1% of 100,000 is 1000 people running around who may or may not have the virus.
Can't base a national strategy on that nonsense when there's a 100% option available. Like you say, why would you risk that.
Yep, interest is definitely there. I reckon they're selling into it to help one of the shorts exit.
No 2. on most followed companies on Vox today which is usually a good indicator on our exchange:
https://ibb.co/S6gKD48
****************************
Bramley's great for volume updates, he'd have a solid take on it.
This should help clear up some of the news today and the commentary from guys on the GDR board about NCYT's new growth outlook. It's looking more like a mid-market company to come.
Share price likely held back today as short positions from Voleon and Airain need closed but will fly soon. Outlook is massive.
Enjoy:
https://www.share-talk.com/novacyt-s-a-ncyt-l-significant-new-opportunities-for-growth/#gs.ba24h9
https://www.share-talk.com/novacyt-s-a-ncyt-l-significant-new-opportunities-for-growth/#gs.ba21qp
Check this link tomorrow or Wednesday and I'd bet we'll see an update on a short being reduced. Would explain why price has been held back and set at 290p for the time being. Clearly at this stage you can tell the price is heavily controlled, so it's all about orders and deals. This will fly once all that nonsense is filled.
https://bdif.amf-france.org/en_US/Resultat-de-recherche-BDIF?formId=BDIF&DOC_TYPE=BDIF&LANGUAGE=en&subFormId=dpcn&BDIF_TYPE_INFORMATION=BDIF_TYPE_INFORMATION_DPCN&TEXT=&BDIF_RAISON_SOCIALE=NOVACYT&bdifJetonSociete=RS00005391&REFERENCE=&DATE_PUBLICATION=&DATE_OBSOLESCENCE=&valid_form=Start+search&isSearch=true
Alright fair enough RBM. We should have really had threads going on each are today. Antibody, Winter testing, 2 gene etc
But instead we're spam replying to an attempt to deramp the share price. A bit of banter is fine, but to be sustained like this is a bit unusual.
I'll filter for a few weeks.
@ Badmashy, yes I agree it's bad form, but solstace did come to NCYT this morning and spam it with misinformation then continued here.
More misinformation he spread here was that the multi gene test is 'new'. It's not. It's the old way of testing. A scattergun approach from when PCT testing was in it's 'infancy' as you can read about here:
https://blog.primerdesign.co.uk/1-vs-2-gene-covid-19-assay-find-out-from-our-experts-which-is-best-for-testing-during-the-covid-19-pandemic/
From listening to Dr. Brinie last week he made it very clear that testing design is really hard to get right. SO many companies now trying to put out a decent test, but when they get it to market and mass test it, the accuracy consistently drops. Because the test ultimately is flawed and the more you test it, and the more slight mutations develop, the more your test misses and falls out off favour.
That's why NCYT developed a new way forward earlier in the year, something the NHS and PHE wanted. The gold standard as it became known around the world.
You should go and check the PrimerDesign webinar last week, they really are brilliant there.